Cannabigerol (CBG) has started to attract serious attention in both research and the cannabinoid industry.
Known as the “mother cannabinoid,” CBG is the precursor from which other cannabinoids such as THC and CBD are formed. Unlike THC, it is non-psychoactive, making it an appealing option for research into health-related applications.
While CBD has been widely studied, CBG is now emerging as a compound worth investigating especially in the field of oncology. One of the most urgent areas of interest is brain cancer, particularly glioblastoma, a cancer that remains one of the most aggressive and difficult to treat.
In this article, we look at the current evidence, focusing on a key study while also exploring what is known so far about cannabinoids and cancer.
CBG (cannabigerol) is a minor cannabinoid found in the hemp plant. It plays a key role in the synthesis of CBD and THC. Although it is usually present in low concentrations, it can be extracted in higher amounts from specially bred strains.
Research suggests CBG interacts with both CB1 and CB2 receptors in the endocannabinoid system, but differently compared to CBD or THC.
For businesses in Europe, this differentiation is important, as regulations in the EU limit marketing claims depending on psychoactivity and clinical evidence.
Brain cancer, particularly glioblastoma multiforme (GBM), is one of the most lethal cancers. Median survival is often less than 18 months even with surgery, chemotherapy, and radiation.
Traditional treatments are limited by the difficulty of delivering drugs across the blood-brain barrier and the aggressive nature of tumor cells. This explains why research into alternative compounds such as cannabinoids is considered urgent.
In the European Union, where there is strong emphasis on evidence-based medicine and compliance, the focus is on early-stage research while regulatory frameworks are being established.
This research is important:
One of the most important studies on CBG and brain cancer came from Cells in 2021 (Nabissi M. et al.).
The researchers tested how CBG affects glioblastoma cells in lab models. Their findings were striking: CBG decreased tumor cell survival and triggered apoptosis, particularly targeting glioblastoma stem-like cells which are notorious for driving recurrence and treatment resistance.
Building on this, a comprehensive 2024 review confirmed that CBG both alone and when combined with CBD promotes apoptosis in glioblastoma stem cells and inhibits invasive tumour behavior. Notably, it also regulates key cancer pathways including GPR55 and TRPV1 signaling.
The review demonstrated that CBG could cross the blood–brain barrier, suggesting improved delivery for brain-targeted therapies.
To make this clearer:
These lab findings offer compelling preclinical evidence. Still, the clinical horizon remains distant: no human trials have yet confirmed safety or effectiveness in brain cancer patients.
Cannabinoids like CBD, THC, and CBG interact with the body in unique ways, particularly through the endocannabinoid system. CBG binds weakly to CB1 receptors in the brain but shows stronger activity at CB2 receptors in the immune system.
In oncology research, proposed mechanisms include inducing apoptosis (programmed cell death), slowing tumor proliferation, blocking angiogenesis (blood vessel growth that fuels tumors), and even targeting glioblastoma stem-like cells that often drive recurrence.
Preclinical work has expanded this picture across different cannabinoids.
For example, CBD has been shown to inhibit tumor growth and metastasis in certain cancers .
THC has also demonstrated the ability to trigger cancer cell death, though its psychoactive effects and side effects remain a challenge for medical use.
Beyond brain cancers, CBG itself has been linked to reduced growth of colorectal cancer cells in laboratory studies.
Together, these findings suggest a growing scientific basis for cannabinoids in oncology. Still, researchers stress that most of this evidence is preclinical, and large-scale clinical trials are needed before cannabinoids can move from experimental findings to standard cancer care.
CBG interacts with the endocannabinoid system differently than CBD and THC. It binds weakly to CB1 receptors in the brain but has stronger interactions with CB2 receptors in the immune system. Proposed mechanisms in cancer research include:
These mechanisms highlight why researchers are increasingly exploring CBG in oncology contexts.
While laboratory and animal studies show promising effects, they cannot fully predict how CBG will work in humans.
Factors such as dosage, safety, metabolism, and long-term effects can only be properly assessed through clinical trials. To date, no human study has demonstrated that CBG is an effective treatment for brain cancer. This gap is especially important in Europe, where strict EU regulations prohibit businesses from marketing cannabinoids as cancer therapies without validated clinical evidence.
Until such trials are completed, CBG should be discussed only as a compound of scientific interest with potential, not as a proven treatment.
In Europe, the conversation around cannabinoids like CBG is shaped by strict regulations. The European Food Safety Authority (EFSA) and national bodies require that any medical or therapeutic claims be backed by clinical trials.
Since such trials are still in early stages for CBG and cancer, companies focus instead on wellness, research, and product development applications.
This approach has encouraged interest in high-quality raw materials that can be used in compliant ways such as formulations for wellness products, nutraceuticals, or ongoing research projects.
Suppliers like WeeDutch, offering CBG Isolate and other wholesale cannabinoids, provide businesses with materials that meet industry standards and allow them to participate in this emerging market responsibly.
The question of whether CBG is useful for brain cancer remains open, but the early evidence is promising.
The 2021 study discussed above demonstrated that CBG reduced glioblastoma cell viability in the lab and targeted cancer stem-like cells. Additional research on cannabinoids like CBD and THC reinforces the potential role of these compounds in oncology.
However, without human trials, CBG cannot be considered a treatment.
For the European market, compliance with strict regulations is essential, and businesses must communicate carefully about research findings. Still, the future of cannabinoids in brain cancer research is one of the most exciting developments in the industry.
We at WeeDutch can provide the high-quality cannabinoids needed to support innovation while ensuring adherence to EU standards.
Please fill in the form below. We will get back to you as soon as possible, usually within 24 hours.
Spannabis is the ultimate event for cannabis professionals and enthusiasts, drawing over 35,000 visitors each year. With exhibitions showcasing the latest innovations in cannabis cultivation,
Spannabis is the ultimate event for cannabis professionals and enthusiasts, drawing over 35,000 visitors each year. With exhibitions showcasing the latest innovations in cannabis cultivation,
CANNABUZZ represents the next generation of cannabinoid vapes in Europe. Our THCNM vapes combine premium quality, advanced formulations, and full compliance with all European regulations.
You are here:
Would you like to receive the brochure about our patented cannabinoid formulas for insomnia, obesity and depression? Fill in your email en receive it direcly!
Would you like to receive the CoA, to ensure the quantity of cannabinoids in this product? Fill in your email en receive it direcly!
